N4BP1: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Target Name: N4BP1

NCBI ID: G9683

N4BP1

N4BP1: A Potential Drug Target and Biomarker for ALZHEIMER'S DISEASE

Alzheimer's disease is a progressive neurological disorder that affects millions of people worldwide, leading to a significant impact on an individual's quality of life. The most common cause of dementia is the neurodegeneration, which is characterized by the progressive loss of brain cells. Alzheimer's disease is the most common form of neurodegeneration, accounting for approximately 60% of all cases. The progressive nature of the disease makes it difficult to develop effective treatments, which primarily focus on managing symptoms and improving quality of life.

Recent studies have identified several potential drug targets and biomarkers for Alzheimer's disease. One of these targets is N4BP1, which is a non-coding RNA (ncRNA) located in the brain. N4BP1 has been shown to be involved in the regulation of various cellular processes, including inflammation, cellular signaling, and neurodegeneration. Its potential as a drug target makes it an attractive target for researchers to investigate and develop new treatments for Alzheimer's disease.

N4BP1: A Potential Drug Target

N4BP1 is a non-coding RNA that is expressed in various tissues and cells, including the brain. It is characterized by a unique structure, which consists of a long intergenic DNA region that is transcribed into a unique protein. The protein encoded by N4BP1 has several known functions, including regulating the expression of genes involved in inflammation, stress response, and neurodegeneration.

One of the well-established functions of N4BP1 is its role in the regulation of inflammation. Chronic inflammation is a major contributor to the development and progression of Alzheimer's disease. Several studies have shown that the expression of pro-inflammatory genes is increased in individuals with Alzheimer's disease compared to age-matched control individuals. The presence of these genes makes them more susceptible to neurodegeneration and cognitive impairment.

N4BP1 has also been shown to play a role in regulating cellular signaling. It has been shown to regulate the activity of several signaling pathways, including TGF-β, NF-kappa-B, and PI3K. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and inflammation. The regulation of these signaling pathways by N4BP1 may be involved in the development and progression of neurodegeneration in Alzheimer's disease.

Furthermore, N4BP1 is involved in the regulation of neurodegeneration. Several studies have shown that the expression of N4BP1 is decreased in individuals with Alzheimer's disease compared to age-matched control individuals. The decreased expression of N4BP1 may contribute to the neurodegeneration that is observed in Alzheimer's disease.

N4BP1 as a Biomarker

The development of new diagnostic tests and biomarkers for Alzheimer's disease is a promising direction in the field. N4BP1 is a potential biomarker for Alzheimer's disease due to its involvement in several cellular processes that are involved in the development and progression of the disease.

N4BP1 has been shown to be involved in the regulation of the neurotransmitter dopamine, which is involved in various cellular processes, including motivation, pleasure, and reward. Studies have shown that individuals with Alzheimer's disease have lower levels of dopamine compared to age-matched control individuals. This decrease in dopamine may contribute to the loss of motivation, pleasure, and reward that is observed in the disease.

N4BP1 has also been shown to be involved in the regulation of the microglial cell, which is a type of immune cell that is involved in inflammation. Studies have shown that individuals with Alzheimer's disease have increased levels of microglial cells compared to age-matched control individuals. This increase in microglial cells may contribute to the chronic inflammation observed in the disease.

In conclusion, N4BP1 is a non-coding RNA that is involved in several cellular processes that are involved in the development and progression of Alzheimer's disease. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate and develop new treatments for the disease. Further studies are needed to fully understand the role of N4BP1 in

Protein Name: NEDD4 Binding Protein 1

Functions: Potent suppressor of cytokine production that acts as a regulator of innate immune signaling and inflammation. Acts as a key negative regulator of select cytokine and chemokine responses elicited by TRIF-independent Toll-like receptors (TLRs), thereby limiting inflammatory cytokine responses to minor insults. In response to more threatening pathogens, cleaved by CASP8 downstream of TLR3 or TLR4, leading to its inactivation, thereby allowing production of inflammatory cytokines (By similarity). Acts as a restriction factor against some viruses, such as HIV-1: restricts HIV-1 replication by binding to HIV-1 mRNAs and mediating their degradation via its ribonuclease activity (PubMed:31133753). Also acts as an inhibitor of the E3 ubiquitin-protein ligase ITCH: acts by interacting with the second WW domain of ITCH, leading to compete with ITCH's substrates and impairing ubiquitination of substrates (By similarity)

The "N4BP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about N4BP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets